These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 36768456)
21. Tachykinin receptors in the small intestine of the cane toad (Bufo marinus): a radioligand binding and functional study. Burcher E; Warner FJ Naunyn Schmiedebergs Arch Pharmacol; 1998 Jun; 357(6):692-700. PubMed ID: 9686947 [TBL] [Abstract][Full Text] [Related]
22. The effect of CP96,345 on the expression of tachykinins and neurokinin receptors in acute pancreatitis. Lau HY; Bhatia M J Pathol; 2006 Feb; 208(3):364-71. PubMed ID: 16369913 [TBL] [Abstract][Full Text] [Related]
23. Characterization of tachykinin receptors mediating bronchomotor and vasodepressor responses to neuropeptide gamma and substance P in the anaesthetized rabbit. Yuan L; Burcher E; Nail BS Pulm Pharmacol Ther; 1998 Feb; 11(1):31-9. PubMed ID: 9802961 [TBL] [Abstract][Full Text] [Related]
24. Tachykinins and tachykinin receptors in bone. Goto T; Tanaka T Microsc Res Tech; 2002 Jul; 58(2):91-7. PubMed ID: 12203708 [TBL] [Abstract][Full Text] [Related]
25. Inflammatory and motor responses by tachykinins in the guinea-pig oesophageal sphincter. Conte B; Parlani M; Lopez G; Cirillo R; Maggi CA; Manzini S J Auton Pharmacol; 1998 Oct; 18(5):313-7. PubMed ID: 9831232 [TBL] [Abstract][Full Text] [Related]
26. Autoradiographic distribution of brain neurokinin-1/substance P receptors using a highly selective ligand [3H]-[Sar9,Met(O2)11]-substance P. Dam TV; Martinelli B; Quirion R Brain Res; 1990 Oct; 531(1-2):333-7. PubMed ID: 1705154 [TBL] [Abstract][Full Text] [Related]
27. Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3. Leffler A; Ahlstedt I; Engberg S; Svensson A; Billger M; Oberg L; Bjursell MK; Lindström E; von Mentzer B Biochem Pharmacol; 2009 May; 77(9):1522-30. PubMed ID: 19426690 [TBL] [Abstract][Full Text] [Related]
28. Do Substance P and Neurokinin A Play Important Roles in the Control of LH Secretion in Ewes? Fergani C; Mazzella L; Coolen LM; McCosh RB; Hardy SL; Newcomb N; Grachev P; Lehman MN; Goodman RL Endocrinology; 2016 Dec; 157(12):4829-4841. PubMed ID: 27704950 [TBL] [Abstract][Full Text] [Related]
29. Electrophysiological effects of tachykinins and capsaicin on guinea-pig bronchial parasympathetic ganglion neurones. Myers AC; Undem BJ J Physiol; 1993 Oct; 470():665-79. PubMed ID: 7508508 [TBL] [Abstract][Full Text] [Related]
31. Expression of Tachykinins and Tachykinin Receptors and Interaction with Kisspeptin in Human Granulosa and Cumulus Cells. García-Ortega J; Pinto FM; Prados N; Bello AR; Almeida TA; Fernández-Sánchez M; Candenas L Biol Reprod; 2016 Jun; 94(6):124. PubMed ID: 27146034 [TBL] [Abstract][Full Text] [Related]
32. Altered expression of the tachykinins substance P/neurokinin A/hemokinin-1 and their preferred neurokinin 1/neurokinin 2 receptors in uterine leiomyomata. González-Santana A; Marrero-Hernández S; Dorta I; Hernández M; Pinto FM; Báez D; Bello AR; Candenas L; Almeida TA Fertil Steril; 2016 Nov; 106(6):1521-1529. PubMed ID: 27456549 [TBL] [Abstract][Full Text] [Related]
34. Substance P and the Neurokinin-1 Receptor: The New CRF. Schank JR; Heilig M Int Rev Neurobiol; 2017; 136():151-175. PubMed ID: 29056150 [TBL] [Abstract][Full Text] [Related]
35. Chimeric NK1 (substance P)/NK3 (neurokinin B) receptors. Identification of domains determining the binding specificity of tachykinin agonists. Gether U; Johansen TE; Schwartz TW J Biol Chem; 1993 Apr; 268(11):7893-8. PubMed ID: 7681831 [TBL] [Abstract][Full Text] [Related]
36. Tachykinin-1 receptor antagonism suppresses substance-P- and compound 48/80-induced mast cell activation from rat mast cells expressing functional mas-related GPCR B3. Sahid MNA; Liu S; Mogi M; Maeyama K Inflamm Res; 2020 Mar; 69(3):289-298. PubMed ID: 31993675 [TBL] [Abstract][Full Text] [Related]
37. The neuropeptide substance P/neurokinin-1 receptor system and diabetes: From mechanism to therapy. Kokabi F; Ebrahimi S; Mirzavi F; Ghiasi Nooghabi N; Hashemi SF; Hashemy SI Biofactors; 2023; 49(3):534-559. PubMed ID: 36651605 [TBL] [Abstract][Full Text] [Related]
38. Substance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK1 receptors. Palma C; Nardelli F; Manzini S; Maggi CA Br J Cancer; 1999 Jan; 79(2):236-43. PubMed ID: 9888463 [TBL] [Abstract][Full Text] [Related]
39. Substance P enhances the local activation of NK Jeong YM; Cheng XW; Lee KH; Lee S; Cho H; Kim W BMC Mol Cell Biol; 2020 Jun; 21(1):41. PubMed ID: 32517655 [TBL] [Abstract][Full Text] [Related]
40. Tachykinin NK1 receptor antagonist L-733,060 and substance P deletion exert neuroprotection through inhibiting oxidative stress and cell death after traumatic brain injury in mice. Li Q; Wu X; Yang Y; Zhang Y; He F; Xu X; Zhang Z; Tao L; Luo C Int J Biochem Cell Biol; 2019 Feb; 107():154-165. PubMed ID: 30593954 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]